Bristol-Myers Squibb News

when Teva announced the hiring of Levin, hopeful his "Big Pharma" background and especially his recent success at Bristol-Myers Squibb (BMY) would help shake Teva out of its doldrums. Those investors/analysts subsequently became nervous when Levin's "deep

Analyst Blog: Dr. Reddy’s Laboratories (RDY - Snapshot Report) recently announced the U.S. launch of a generic version of Bristol-Myers Squibb & Co.’s (BMY - Analyst Report) blood thinner, Plavix. The U.S. Food and Drug Administration (FDA) approved the Abbreviated

Reddy's Laboratories ( RDY ) recently announced the U.S. launch of a generic version of Bristol-Myers Squibb & Co. 's ( BMY ) blood thinner, Plavix. The U.S. Food and Drug Administration (FDA) approved the Abbreviated New Drug Application (ANDA) for 75 mg

week marks the end of an era for Bristol-Myers Squibb. The big-selling Plavix bloodthinner lost patent protection and the FDA promptly approved several generic versions. Given that the medication generated billions of dollars a year in revenue for the drugmaker

$0.64. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. On average, analysts predict that Bristol Myers Squibb will post $0.41 earnings per share next quarter. Separately, analysts at Zacks reiterated a “neutral” rating on shares

& Co. (LLY) and AstraZeneca Plc (AZN) won’t have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co. (BMY)’s Plavix after the drug lost U.S. patent protection yesterday. Lilly’s Effient and AstraZeneca’s Brilinta

Shares of Gap Inc. (NYSE:GPS) jumped more than 4 percent in late trading. The company announced first-quarter net income of $233 million (47 cents per share). Revenue increased 5.8 percent to $3.49 billion from the year-earlier quarter. “During the quarter

Squibb (NYSE: BMY) and Sanofi (NYSE: SFY) bid goodbye to their exclusive patent for blockbuster drug Plavix with the U.S. Food and Drug Administration’s approval of generic versions of the blood-thinning drug to nine pharmaceutical companies today, signaling

is a blood thinner from Bristol-Myers Squibb ($BMY). Generic Plavix is a Bristol-Myers profits thinner that is going to be produced by just about everybody and their brother. The FDA on Thursday approved a long list of companies that supply clopidogrel, the

might learn from his alleged mistakes. Read at Pharmalot Read at The Australian Read at News Release Read at Wall Street Journal • Pharmalot • The Australian • News Release • Wall Street Journal • Bristol-Myers Squibb Company • Biotech/Pharma - Background